KTE-X19

brexucabtagene autoleucel · Kite Pharma (a Gilead Sciences company)

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for KTE-X19, covering 2025-12-16 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]